Clinical usefulness of free light chain concentration as a tumor marker in multiple myeloma Ann Hematol 2005;84:588-93.So-Young Kang, Jin-Tae Suh, Hee-Joo Lee, et al. Clinical usefulness of free light chain concentration as a tumor marker in multiple myeloma[J]. Hematol, 2005,84: 588-...
cancer that involves a type of white blood cell called a plasma (or myeloma) cell. The tumor cells in myeloma can form a single collection (plasmacytoma) or many tumors (multiple myeloma). Plasma cells are normally part of theimmune system; they make antibodies. Because myeloma patients have ...
Multiple myeloma (MM) is a malignant plasma cell disease in which tumor cells originate from plasma cells in the bone marrow, and plasma cells are cells that develop to the final stage of function of B lymphocytes. Therefore, multiple myeloma can be classified as B lymphocyte lymphoma. The WH...
Previous studies of myeloma immunoglobulin synthesis and tumor cell number, using a marker kinetic approach, have increased knowledge about body burden of
Objective Beta‐2‐microglobulin is a serum marker of tumor burden in multiple myeloma (MM). Our aim was to correlate serum β‐microglobulin levels in patients with MM to tumor burden determined by low‐dose whole‐body CT (LDWBCT). Materials and Methods A total of 52 patients with newly ...
Interactions between multiple myeloma (MM) and bone marrow (BM) are well documented to support tumour growth, yet the cellular mechanisms underlying pain in MM are poorly understood. We have used in vivo murine models of MM to show significant induc
the complex cross-talk between myeloma cells and surrounding non-cancer cells results in the successful growth of malignant subclones, with impacts on clonal revolution and resistance to therapies. MM: multiple myeloma; MMSCs: multiple myeloma stem cells; TME: tumor microenvironment; BM: bone ...
The approach is based on quantitative studies of M component synthesis by human myeloma cells in vitro and in vivo. These measurements of the tumor's marker protein are then used as a means to calculate the total body burden of tumor cells in this disorder. The technique provides the basis ...
The interaction between multiple myeloma (MM) cells and the bone marrow stroma constitutes the basis of myeloma pathogenesis and has led the way for the corresponding therapeutic strategies. The aim of this study is to evaluate tumor-associated macrophages (TAMs) which is an important element of ...
Multiple myeloma (MM) is a treatable plasma cell cancer with no cure. Clinical evidence shows that the status of minimal residual disease (MRD) after treatment is an independent prognostic factor of MM. MRD indicates the depth of post-therapeutic remissi